Dataset Information

A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.

ABSTRACT: CMT1A is the most common inherited peripheral neuropathy. There is currently no approved treatment. We performed a meta-analysis including four randomized, double-blind, Placebo-controlled clinical trials to assess the disease progression after one year under Placebo, Ascorbic Acid (AA) or PXT3003, a combination of three repurposed drugs. We observed a weak deterioration in patients under Placebo, well below the reported natural disease progression. Patients treated with AA were stable after one year but not significantly different from Placebo. Patients undergoing PXT3003 treatment showed an improvement in CMTNS and ONLS, statistically significant versus Placebo and potentially precursory of a meaningful change in the disease course.

SUBMITTER: Mandel J

PROVIDER: S-EPMC4482281 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.

Mandel Jonas J Bertrand Viviane V Lehert Philippe P Attarian Shahram S Magy Laurent L Micallef Joëlle J Chumakov Ilya I Scart-Grès Catherine C Guedj Mickael M Cohen Daniel D

Orphanet journal of rare diseases 20150613

CMT1A is the most common inherited peripheral neuropathy. There is currently no approved treatment. We performed a meta-analysis including four randomized, double-blind, Placebo-controlled clinical trials to assess the disease progression after one year under Placebo, Ascorbic Acid (AA) or PXT3003, a combination of three repurposed drugs. We observed a weak deterioration in patients under Placebo, well below the reported natural disease progression. Patients treated with AA were stable after one ...[more]

PMID: 26070802

Similar Datasets

Project description:Human milk provides necessary macronutrients (protein, carbohydrate, fat) required for infant nutrition. Lactoferrin (Lf), a multifunctional iron-binding protein predominant in human milk, shares similar protein sequence, structure, and bioactivity with bovine Lf (bLf). This large-scale pediatric nutrition study was designed to evaluate growth and tolerance in healthy infants who received study formulas with bLf at concentrations within the range of mature human milk.In this multi-center, double-blind, parallel-designed, gender-stratified prospective study 480 infants were randomized to receive a marketed routine cow's milk-based infant formula (Control; n?=?155) or one of two investigational formulas with bLf at 0.6 g/L (LF-0.6; n?=?165) or 1.0 g/L (LF-1.0; n?=?160) from 14-365 days of age. Investigational formulas also had a prebiotic blend of polydextrose (PDX) and galactooligosaccharides (GOS) and adjusted arachidonic acid (ARA). The primary outcome was weight growth rate from 14-120 days of age. Anthropometric measurements were taken at 14, 30, 60, 90, 120, 180, 275, and 365 days of age. Parental recall of formula intake, tolerance, and stool characteristics was collected at each time point. Medically-confirmed adverse events were collected throughout the study period.There were no group differences in growth rate (g/day) from 14-120 days of age; 353 infants completed the study through 365 days of age (110; LF-0.6: 127; LF-1.0: 116). Few differences in growth, formula intake, and infant fussiness or gassiness were observed through 365 day of age. Group discontinuation rates and the overall group incidence of medically-confirmed adverse events were not significantly different. From 30 through 180 days of age, group differences in stool consistency (P?<?0.005) were detected with softer stools for infants in the LF-0.6 and LF-1.0 groups versus CONTROL.Compared to the Control, infants who received investigational formulas with bLf and the prebiotic blend of PDX and GOS experienced a softer stooling pattern similar to that reported in breastfed infants. This study demonstrated routine infant formulas with bLf, a blend of PDX and GOS, and adjusted ARA were safe, well-tolerated, and associated with normal growth when fed to healthy term infants through 365 days of age.ClinicalTrials.gov NCT01122654 . Registered 10 May 2010.

Project description:Background:We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy. Methods:Data from chemotherapy trials MA.5 and MA.21; endocrine therapy MA.12, MA.14 and MA.27; and trastuzumab HERA/MA.24 were analyzed. The primary objective was to examine the effect of BMI change on breast cancer-free interval (BCFI) landmarked at 5 years; secondary objectives included BMI changes at 1 and 3 years; BMI changes on disease-specific survival (DSS) and overall survival (OS); and effects of baseline BMI. Stratified analyses included trial therapy and composite trial stratification factors. Results:In pre-/peri-/early post-menopausal chemotherapy trials (N?=?2793), baseline BMI did not impact any endpoint and increased BMI from baseline did not significantly affect BCFI (P?=?0.85) after 5 years although it was associated with worse BCFI (P?=?0.03) and DSS (P?=?0.07) after 1 year. BMI increase by 3 and 5 years was associated with better DSS (P?=?0.01; 0.01) and OS (P?=?0.003; 0.05). In pre-menopausal endocrine therapy trial MA.12 (N?=?672), patients with higher baseline BMI had worse BCFI (P?=?0.02) after 1 year, worse DSS (P?=?0.05; 0.004) after 1 and 5 years and worse OS (P?=?0.01) after 5 years. Increased BMI did not impact BCFI (P?=?0.90) after 5 years, although it was associated with worse BCFI (P?=?0.01) after 1 year. In post-menopausal endocrine therapy trials MA.14 and MA.27 (N?=?8236), baseline BMI did not significantly impact outcome for any endpoint. BMI change did not impact BCFI or DSS after 1 or 3 years, although a mean increased BMI of 0.3 was associated with better OS (P?=?0.02) after 1 year. With the administration of trastuzumab (N?=?1395) baseline BMI and BMI change did not significantly impact outcomes. Conclusions:Higher baseline BMI and BMI increases negatively affected outcomes only in pre-/peri-/early post-menopausal trial patients. Otherwise, BMI increases similar to those expected in healthy women either did not impact outcome or were associated with better outcomes. Clinical Trials numbers:CAN-NCIC-MA5; National Cancer Institute (NCI)-V90-0027; MA.12-NCT00002542; MA.14-NCT00002864; MA.21-NCT00014222; HERA, NCT00045032;CAN-NCIC-MA24; MA-27-NCT00066573.

Dataset Information

A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.

Publications

A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets